INSIGHTS ON FACILITY DESIGN

  • Moving Towards A Closed CAR T Cell Manufacturing Process

    Challenges to overcome in the CAR T manufacturing process include lengthy production times 11 21 days), product variability associated with open handling steps, and high manufacturing costs Here we examine and evaluate individual CAR T cell unit operations, commercial reagents, and equipment with process closure potential to develop an improved workflow and increase product consistency.

  • Your Strategy To Manufacture, No Longer A One-Size-Fits-All
    Your Strategy To Manufacture, No Longer A One-Size-Fits-All

    The traditional method of big batch manufacturing must change as companies move away from the one-size-fits-all blockbuster model toward more innovative, targeted biologics that deliver better outcomes.

  • Guidelines To Bring Your Biologic To Market: Are You Prepared?
    Guidelines To Bring Your Biologic To Market: Are You Prepared?

    Are you up to the task of bringing a biologic drug to market? Do you have a strategy and plan for moving forward? Here we explore, from a biopharma process development and manufacturing perspective.

  •   Modular Bioprocessing Alleviates Drug Manufacturing Woes
    Modular Bioprocessing Alleviates Drug Manufacturing Woes

    Building a bioprocessing facility is usually a complicated process and requires partnering with not only drug developers, but also many different experts in various industries.

More Insights On Facility Design

FACILITY DESIGN SOLUTIONS

  • Ibex™ Dedicate

    As the biopharma industry identifies faster and more efficient ways to deliver drugs to patients, such as break-through and fast track designations for accelerated approval, these progresses create pressure on both large and small drug manufacturers. As development timelines shorten, decisions related to drug commercialization need to be taken earlier, when key results are not yet available. And deciding on the scale and type of facility to build without complete data can create substantial risks with costly consequences.

  • GE Life Sciences Overview - Cell Processing

    Helping your cell therapies succeed through our reach and resources.

  • Genderless AseptiQuik® L Series Connectors
    Genderless AseptiQuik® L Series Connectors

    Genderless AseptiQuik® L Connectors enable quick and easy sterile connections, in large-volume, high-flow production environments. The largeformat, 3/4" and 1" genderless design simplifies system integration and minimizes the risk of operator error. The connectors’ robust construction provides reliable performance without the need for clamps, fixtures or tube welders. Biopharmaceutical manufacturers benefit from interchangeable 3/4” and 1” flow solutions for full-scale bioprocessing production environments with the quality and market availability they expect from the leader in single-use connection technology.

  • Genderless AseptiQuik® L Series Connectors Datasheet

    Genderless AseptiQuik® L Connectors enable quick and easy sterile connections, in large-volume, high-flow production environments. The largeformat, 3/4" and 1" genderless design simplifies system integration and minimizes the risk of operator error.

  • Cleanroom PODs® with LifeAire Systems

    PODs coupled with LifeAire Systems’ purification technology offers extreme cleanliness and stability of the air in G-CON‘s prefabricated cleanrooms. This is achieved with LifeAire’s proven and patented multi-stage filtration systems built within the POD, eliminating all toxic airborne pathogens within critical space environments on a single pass. LifeAire’s new, transformational and proven technology provides deliverables that exceed GMP metrics that have been recognized as toxic to living cell culture.

More Facility Design Solutions